Clinical Trial Update: Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) [Phase 2]

View source ↗

Summary

An exploratory Phase 2 study evaluating VHAG (venetoclax, homoharringtonine, azacitidine, plus G-CSF) for newly diagnosed acute myeloid leukemia; the trial is n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Granulocyte Colony Stimulating Factor (granulocyte colony-stimulating factor (G-CSF))
• Homoharringtonine (homoharringtonine)
• Venetoclax (venetoclax)

Snippet

Sponsor: First People's Hospital of Hangzhou | Conditions: Acute Myeloid Leukemia (AML) | Phase 2 | Status: NOT_YET_RECRUITING